Search

Jardiance® Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway

Results from the INJOURNEY™ trial investigating Ofev® with add-on pirfenidone provide new insights into this combination treatment for IPF

Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease

FDA Grants Fast Track to Jardiance® (empagliflozin) for CKD | Boehringer Ingelheim US

The FDA has granted Fast Track designation for JARDIANCE to reduce risk of disease progression and CV death with CKD. View ISI, PI & Med Guide.

FDA Advisory Committee Recommends Approval of Tiotropium Respimat® for the Maintenance Treatment of COPD

FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype

U.S. FDA approves first-in-class Glyxambi® (empagliflozin/linagliptin) tablets for adults with type 2 diabetes

Efficacy and safety of Ofev® (nintedanib) reinforced in new presentations at ATS 2018

Jardiance® (empagliflozin) analysis reinforces established safety profile

Boehringer Ingelheim and Lilly expand heart failure program for Jardiance with new exercise capacity trials

Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of Jardiance® in adults with chronic kidney disease

FDA approves additional formulation of biosimilar

US FDA approves additional formulation of Cyltezo® (adalimumab-adbm). See Important Safety Information including Boxed Warning, Prescribing Information, Medication Guide and Instructions for Use.

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

Boehringer Ingelheim and Lilly Welcome New Recommendation for Jardiance® (empagliflozin) tablets in Updated American Diabetes Association’s 2017 Standards

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

Emmanuelle leads a team of scientists

Want to work for a company that allows you to grow your career? Emmanuelle talks about her job journey at Boehringer Ingelheim.

Our forward-looking approach drives breakthroughs

Our purpose is the patient—so our actions are those of a partner, our vision is always long-term, and our results are measured in lives changed and lives saved.

Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure

FDA Approves Jardiance® (empaglifozin) for T2D | BI US

Read more about the approval of Boehringer Ingelheim's third product from the BI-Lilly Diabetes alliance, JARDIANCE, used to treat type-2 diabetes.

Jardiance® (empagliflozin) Reduces Risk for CV Death | BI US

Analyses show risk reductions were consistent across age groups for CV outcomes with JARDIANCE compared with placebo. View ISI, PI & Med Guide.

New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies

First Patient Enrolled in New Cardiovascular and Renal Outcomes Trial for TRADJENTA® (linagliptin) Tablets in Type 2 Diabetes

SPEVIGO approved for expanded indications in China and the US

FDA approval for the Treatment of Generalized Pustular Psoriasis (GPP) in Adults and Pediatric Patients 12 Years of Age and Older Weighing at Least 40kg

Boehringer Ingelheim Fremont Employee Benefit Highlights

BI Fremont offers an excellent, competitive benefit package that takes care of you & your family. Our benefits package reflects BI’s culture & core values.

FDA Expands Approval of SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers